324 related articles for article (PubMed ID: 32946450)
21. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
22. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
23. Impact of Timely Treatment Intensification on Glycemic Goal Achievement in Patients With Type 2 Diabetes Failing Metformin Monotherapy.
Mahabaleshwarkar R; Templin M; Gohs F; Mulder H; DeSantis A; Ejzykowicz F; Rajpathak S; Wilkins N
Diabetes Educ; 2017 Oct; 43(5):495-505. PubMed ID: 28828933
[TBL] [Abstract][Full Text] [Related]
24. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
27. Progression to treatment failure among Chinese patients with type 2 diabetes initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes Registry.
Jiang G; Luk AO; Yang X; Wang Y; Tam CHT; Lau SH; Ozaki R; Kong APS; Tong PC; Chow CC; Chan JCN; So WY; Ma RCW
Diabetes Res Clin Pract; 2016 Feb; 112():57-64. PubMed ID: 26703273
[TBL] [Abstract][Full Text] [Related]
28. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Gillani SW; Moosvi AF
Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
[TBL] [Abstract][Full Text] [Related]
29. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
30. A historical cohort study of glycemic control in patients with concurrent type 2 diabetes and substance use disorder treated in a primary care setting.
DeYoung OA; Boehmer K; Hung D; McAdam-Marx C
Fam Pract; 2021 Sep; 38(5):562-568. PubMed ID: 33738503
[TBL] [Abstract][Full Text] [Related]
31. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
33. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
[TBL] [Abstract][Full Text] [Related]
34. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Tao T; Wu P; Wang Y; Liu W
BMC Endocr Disord; 2018 Feb; 18(1):14. PubMed ID: 29482528
[TBL] [Abstract][Full Text] [Related]
35. Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program.
Wang K; Zhao S; Lee EK; Yau SZ; Wu Y; Hung CT; Yeoh EK
JAMA Netw Open; 2024 Feb; 7(2):e2355733. PubMed ID: 38345817
[TBL] [Abstract][Full Text] [Related]
36. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
37. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Goldstein BJ; Feinglos MN; Lunceford JK; Johnson J; Williams-Herman DE;
Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
Wang F; He Y; Zhang R; Zeng Q; Zhao X
Medicine (Baltimore); 2017 Sep; 96(36):e7638. PubMed ID: 28885325
[TBL] [Abstract][Full Text] [Related]
39. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
40. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model.
Pantalone KM; Misra-Hebert AD; Hobbs TM; Kong SX; Ji X; Ganguly R; Milinovich A; Weng W; Bauman JM; Petraro P; Burguera B; Zimmerman RS; Kattan MW
Diabetes Care; 2020 Aug; 43(8):1910-1919. PubMed ID: 32527797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
